Alzheimer’s Drugs Market Insights, 2017-2025

Alzheimer’s Drugs Market (Drug class - Cholinergic, Memantine, and Combined Drug; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Alzheimer’s Drugs Market: Snapshot

The research report on the global Alzheimer’s drugs market predicts that the rise in the incidence of Alzheimer’s disease is anticipated to propel the demand for effective drugs for treatment. The report also predicts that the global Alzheimer’s drugs market will expand at a stellar growth rate i.e. 7.5 % over the forecast period of 2017 to 2025 and cross the evaluation of US$ 6.4 billion in 2025 i.e. the end of the forecast period. 

The segments in the global Alzheimer’s drugs market based on the class of drug include mematine, cholinergic, and combined drug, among others. Amongst these, mematine segment is likely to take the lead within the global Alzheimer’s drugs market in coming years. Furthermore, certain products from the combined drugs category are also likely to positively influence the revenue generation in the global Alzheimer’s drugs market in near future. However, lack of availability of effective drugs is also propelling the demand for cholinergic drugs in coming years, with the segment witnessing a significant growth curve within the global Alzheimer’s drugs market.

Hospital Pharmacy Segment Holds Large Share in the Alzheimer’s Drugs Market

Distribution channels used by the manufacturers and players operational within the global Alzheimer’s drugs market include retail pharmacy, hospital pharmacy, and online sales. The rising instances of hospitalization in order to treat Alzheimer’s is boosting the demand within the hospital pharmacy segment in the global Alzheimer’s drugs market. This trend is anticipated to advance the positioning of this segment in the global Alzheimer’s drugs market in coming years.

Few of the major incumbent players working within the global Alzheimer’s drugs market include Novartis AG, H Lundbeck A/S, Ono Pharmaceutical Co. Ltd., Johnson & Johnson, Allergen PLC, Eisai Co Ltd., Daiichi Sankyo Company Limited, and Merz Holding GmbH & Co KG, among others. Manufacturers and players functional within the global Alzheimer’s drugs market are adopting various corporate growth strategies in order to enhance their industry positioning in coming years. Some of the major tactics and strategies utilized by the players in the global Alzheimer’s drugs market include strategic collaborations and partnerships as well as mergers and acquisitions.

Furthermore, increasing requirement of new drug development post drug discovery has given an impetus for players in the global Alzheimer’s drugs market to invest heavily in technological advancements as well as research and development activities. Players in the global Alzheimer’s drugs market are noticed combining two major resources i.e. novel technologies as well as labor in order to take a lead within the industry in terms of product offerings to enhance their market share.

North America Emerges as Leading Region in the Alzheimer’s Drugs Market

Major regions and leading economies assessed thoroughly in the business intelligence study on the global Alzheimer’s drugs market include Europe (including Germany, Italy, the United Kingdom, France, Spain, and rest of the Europe), Latin America (including Brazil, Mexico, and rest of the Latin America), North America (including the United States and Canada), Asia Pacific (including Japan, Australia and New Zealand, China, India, and rest of the Asia Pacific), and Middle East and Africa (including the Gulf Cooperation Council countries, South Africa, and rest of the Middle East and Africa).

Regionally, North America market is anticipated to emerge as the leading regional market in the global Alzheimer’s drugs market in coming years. Some of the key drivers for the development of the global Alzheimer’s drugs market in North America include strong research and development landscape in the region as well as presence of well-established and superior healthcare infrastructure in the region. Furthermore, factors such as presence of a massive number of players in regional pharmaceutical industry, increasing cases of Alzheimer’s in the region, and rising awareness in the region pertaining to this disease are also likely to motivate development within the global Alzheimer’s drugs market in North America in coming years.

Global Alzheimer’s Drugs Market is segmented as below:

by Drug Class

  • Cholinergic
  • Memantine
  • Combined Drug
  • Others

by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the total market worth of alzheimer’s drugs market?

Alzheimer’s drugs market was worth US$3.6 bn and is projected to reach a value of US$6.4 bn by the end of 2025

What is the anticipated CAGR of the alzheimer’s drugs market in the forecast period?

Alzheimer’s drugs market is anticipated to grow at a CAGR of 7.5% during the forecast period

Which region is expected to project the highest market share in the global alzheimer’s drugs market?

North America accounted for a major share of the global alzheimer’s drugs market

What are the key driving factors for the growth of the alzheimer’s drugs market?

Alzheimer’s drugs market is driven by rise in ageing population and increasing occurrence of neurological disorders in the geriatric community around the world

Who are the key players in the global alzheimer’s drugs market?

Key players in the global alzheimer’s drugs market include Allergan plc and Novartis AG. Other leading companies include Johnson and Johnson, Ono Pharmaceutical Co Ltd., Merz Holding GmBH & Co KG, Daiichi Sankyo Company Ltd, and Eisai Co Ltd., among others

    Chapter 1 Preface 
    1.1 Report Scope and Market Segmentation 
    1.2 Research Highlights

    Chapter 2 Assumptions and Research Methodology 
    2.1 Assumptions
    2.2 Research Methodology

    Chapter 3 Executive Summary
    3.1 Alzheimer’s Drugs Market Snapshot, 2016
    3.2 Alzheimer’s Drugs Market: Opportunity Map

    Chapter 4 Market Overview
    4.1 Introduction
    4.2 Global Alzheimer’s Drugs Market Size (US$ Mn) Forecast, 2015–2025
    4.3 Alzheimer’s Drugs Market Outlook 
    4.4 Key Industry Events 

    Chapter 5 Market Dynamics
    5.1 Drivers and Restraints Snapshot Analysis 
    5.2 Drivers 
          5.2.1 Increasing global prevalence of Alzheimer’s 
          5.2.2 Improvising regulatory scenario
          5.2.3 Increasing government funding
          5.2.4 Entry of novel symptomatic therapies 
          5.2.5 Growing social awareness of the disease
    5.3 Restraints
          5.3.1 Alzheimer’s drug failure rate at 99%
          5.3.2 Multifactorial etiology and complex pathophysiology of the disease
          5.3.3 High level of comorbidity occurring in the elderly population
          5.3.4 Expanding diagnostic capability
          5.3.5 Increasing cost for Alzheimer’s drug development
    5.4 Opportunities 
          5.4.1 Reduce the time and risk of AD drug development through an improvement in trial design
          5.4.2 Improving clinical outcomes
    5.5 Trends 
          5.5.1 Development of compounds acting on the main stages of the pathogenesis of the disease (disease-modifying agents
          5.5.2 Focused design of multi targeted drugs acting on multiple molecular targets involved in the pathogenesis of the disease
    5.6 Porter’s Five Forces Analysis
    5.7 PEST Analysis 
    5.8 Pipeline Analysis 
    5.9 Global Prevalence & Incidence
    5.10 Biomarkers Analysis 
    5.11 Most Promising Molecules 

    Chapter 6 Alzheimer’s Drugs Market Analysis by Drug Class
    6.1 Key Findings 
    6.2 Introduction 
    6.3 Global Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
    6.4 Global Alzheimer’s Drugs Market Forecast, by Drug Class 
    6.5 Global Alzheimer’s Drugs Market Analysis, by Drug Class 
    6.6 Global Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class 
    6.7 Key Trends 

    Chapter 7 Alzheimer’s Drugs Market Analysis, by Distribution Channel
    7.1 Key Findings 
    7.2 Introduction 
    7.3 Global Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
    7.4 Global Alzheimer’s Drugs Market Forecast, by Distribution Channel 
    7.5 Global Alzheimer’s Drugs Market Analysis, by Distribution Channel 
    7.6 Global Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel 
    7.7 Key Trends 

    Chapter 8 Alzheimer’s Drugs Market Analysis by Region
    8.1 Global Alzheimer’s Drugs Market Snapshot, by Country 
    8.2 Global Alzheimer’s Drugs Market Value Share Analysis, by Region 
    8.3 Global Alzheimer’s Drugs Market Forecast, by Region 
    8.4 Global Alzheimer’s Drugs Market Attractiveness, by Region 

    Chapter 9 North America Alzheimer’s Drugs Market Analysis
    9.1 Key Findings 
    9.2 North America Alzheimer’s Drugs Market Overview 
    9.3 North America Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
    9.4 North America Alzheimer’s Drugs Market Forecast, by Drug Class
    9.5 North America Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
    9.6 North America Alzheimer’s Drugs Market Forecast, by Distribution Channel 
    9.7 North America Alzheimer’s Drugs Market Value Share Analysis, by Country 
    9.8 North America Alzheimer’s Drugs Market Forecast, by Country 
    9.9 North America Alzheimer’s Drugs Market Attractiveness Analysis 
    9.10 Market Trends 

    Chapter 10 Europe Alzheimer’s Drugs Market Analysis
    10.1 Key Findings 
    10.2 Europe Alzheimer’s Drugs Market Overview 
    10.3 Europe Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
    10.4 Europe Alzheimer’s Drugs Market Forecast, by Drug Class
    10.5 Europe Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
    10.6 Europe Alzheimer’s Drugs Market Forecast, by Distribution Channel 
    10.7 Europe Alzheimer’s Drugs Market Value Share Analysis, by Country 
    10.8 Europe Alzheimer’s Drugs Market Forecast, by Country 
    10.9 Europe Alzheimer’s Drugs Market Attractiveness Analysis 
    10.10 Market Trends 

    Chapter 11 Asia Pacific Alzheimer’s Drugs Market Analysis
    11.1 Key Findings 
    11.2 Asia Pacific Alzheimer’s Drugs Market Overview 
    11.3 Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
    11.4 Asia Pacific Alzheimer’s Drugs Market Forecast, by Drug Class
    11.5 Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
    11.6 Asia Pacific Alzheimer’s Drugs Market Forecast, by Distribution Channel 
    11.7 Asia Pacific Alzheimer’s Drugs Market Value Share Analysis, by Country 
    11.8 Asia Pacific Alzheimer’s Drugs Market Forecast, by Country 
    11.9 Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis 
    11.10 Market Trends 

    Chapter 12 Latin America Alzheimer’s Drugs Market Analysis
    12.1 Key Findings 
    12.2 Latin America Alzheimer’s Drugs Market Overview 
    12.3 Latin America Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
    12.4 Latin America Alzheimer’s Drugs Market Forecast, by Drug Class
    12.5 Latin America Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel 
    12.6 Latin America Alzheimer’s Drugs Market Forecast, by Distribution Channel 
    12.7 Latin America Alzheimer’s Drugs Market Value Share Analysis, by Country 
    12.8 Latin America Alzheimer’s Drugs Market Forecast, by Country 
    12.9 Latin America Alzheimer’s Drugs Market Attractiveness Analysis 
    12.10 Market Trends 

    Chapter 13 Middle East and Africa (MEA) Alzheimer’s Drugs Market Analysis
    13.1 Key Findings 
    13.2 Middle East and Africa Alzheimer’s Drugs Market Overview 
    13.3 Middle East and Africa Alzheimer’s Drugs Market Value Share Analysis, by Drug Class 
    13.4 Middle East and Africa Alzheimer’s Drugs Market Forecast, by Drug Class
    13.5 Middle East and Africa Alzheimer’s Drugs Market Value Share Analysis, by Distribution Channel
    13.6 Middle East and Africa Alzheimer’s Drugs Market Forecast, by Distribution Channel 
    13.7 Middle East and Africa Alzheimer’s Drugs Market Value Share Analysis, by Country 
    13.8 Middle East and Africa Alzheimer’s Drugs Market Forecast, by Country 
    13.9 Middle East and Africa Alzheimer’s Drugs Market Attractiveness Analysis 
    13.10 Market Trends 

    Chapter 14 Company Profiles
    14.1 Alzheimer’s Market Share Analysis By Company 
    14.2 Competition Matrix 
    14.3 Company Profiles
          14.3.1 Allergan plc
                   14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.1.2 Product Portfolio
                   14.3.1.3 SWOT Analysis
                   14.3.1.4 Strategic Overview
          14.3.2 Novartis AG
                   14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.2.2 Product Portfolio
                   14.3.2.3 SWOT Analysis
                   14.3.2.4 Strategic Overview
          14.3.3 Eisai Co Ltd
                   14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.3.2 Product Portfolio
                   14.3.3.3 SWOT Analysis
                   14.3.3.4 Strategic Overview
          14.3.4 Johnson & Johnson
                   14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.4.2 Product Portfolio
                   14.3.4.3 SWOT Analysis
                   14.3.4.4 Strategic Overview
          14.3.5 Daiichi Sankyo Company Limited
                   14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.5.2 Product Portfolio
                   14.3.5.3 SWOT Analysis
                   14.3.5.4 Strategic Overview
          14.3.6 Ono Pharmaceutical Co Ltd
                   14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.6.2 Product Portfolio
                   14.3.6.3 SWOT Analysis
                   14.3.6.4 Strategic Overview
          14.3.7 H Lundbeck A/S
                   14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.7.2 Product Portfolio
                   14.3.7.3 SWOT Analysis
                   14.3.7.4 Strategic Overview
          14.3.8 Merz Holding GmbH & Co KG
                   14.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.8.2 Product Portfolio
                   14.3.8.3 SWOT Analysis
                   14.3.8.4 Strategic Overview

    List of Tables

    Table 1: Alzheimer's Drugs: Pipeline Analysis – Phase III
    Table 2: Alzheimer's Drugs: Pipeline Analysis – Phase II
    Table 3: Alzheimer's Drugs: Pipeline Analysis – Phase I
    Table 4: Prevalence and Incidence by Global and Region 
    Table 5: Prevalence by Country and Region
    Table 6: Biomarker Analysis List in Alzheimer’s Drug Market
    Table 7: Most Promising Molecules List
    Table 8: Global Alzheimer's Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 9: Global Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 10: Global Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 11: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 12: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 13: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 14: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 15: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 16: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 17: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 18: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 19: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 20: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 21: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 22: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 23: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 24: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 25: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025

    List of Figures

    Figure 1: Alzheimer's Drugs Market Snapshot, 2016
    Figure 2: DROT Executive Summary
    Figure 3: Market Share Executive Summary
    Figure 4: Drug Class Revenue Share, 2016
    Figure 5: Distribution Channel Revenue Share, 2016
    Figure 6: Global Alzheimer's Drugs Market Size (US$ Mn) Forecast, 2015–2025
    Figure 7: Market Value Share, by Drug Class (2016
    Figure 8: Market Value Share, by Distribution Channel (2016)
    Figure 9: Market Value Share, by Region (2016)
    Figure 10: Key Industry Events 
    Figure 11: Global Alzheimer's Drugs Market Value Share, by Drug Class, 2017 and 2025
    Figure 12: Global Cholinergic Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 13: Global Memantine Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 14: Global Combined Drug Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 15: Global Others Drug Class Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 16: Global Alzheimer's Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 17: Global Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 18: Global Hospital Pharmacy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 19: Global Retail Pharmacy Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 20: Global Online Sales Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 21: Global Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 22: Global Alzheimer’s Drugs Market Value Share, by Region, 2017 and 2025
    Figure 23: Global Alzheimer’s Drugs Market Attractiveness Analysis, by Region, 2017–2025
    Figure 24: North America Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 25: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017–2025
    Figure 26: North America Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
    Figure 27: North America Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 28: North America Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
    Figure 29: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 30: North America Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 31: Europe Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 32: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017–2025
    Figure 33: Europe Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
    Figure 34: Europe Alzheimer's Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 35: Europe Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
    Figure 36: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 37: Europe Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 38: Asia Pacific Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 39: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017-2025
    Figure 40: Asia Pacific Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
    Figure 41: Asia Pacific Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 42: Asia Pacific Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
    Figure 43: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 44: Asia Pacific Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 45: Latin America Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 46: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017-2025
    Figure 47: Latin America Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
    Figure 48: Latin America Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 49: Latin America Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
    Figure 50: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 51: Latin America Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 52: Middle East & Africa Alzheimer’s Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 53: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Country, 2017-2025
    Figure 54: Middle East & Africa Alzheimer’s Drugs Market Value Share, by Drug Class, 2017 and 2025
    Figure 55: Middle East & Africa Alzheimer’s Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Figure 56: Middle East & Africa Alzheimer’s Drugs Market Value Share, by Country, 2017 and 2025
    Figure 57: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Drug Class, 2017–2025
    Figure 58: Middle East & Africa Alzheimer’s Drugs Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 59: Global Alzheimer’s Market Share Analysis By Company (2016)
    Figure 60: Allergan plc Breakdown of Net Sales (%), by Business Segment, 2016
    Figure 61: Allergan plc Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 62: Novartis Breakdown of Net Sales, by Business segments, 2016
    Figure 63: Novartis Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 64: Eisai Breakdown of Net Sales, by Region, 2016
    Figure 65: Eisai Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 66: Johnson Breakdown of Net Sales, by Region, 2016
    Figure 67: Johnson Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 68: Daiichi Breakdown of Net Sales, by Region, 2016
    Figure 69: Daiichi Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 70: Ono Breakdown of Net Sales, by Region, 2016
    Figure 71: Ono Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 72: Lundbeck Breakdown of Net Sales, by Region 2016
    Figure 73: Lundbeck Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 74: Merz Breakdown of Net Sales, by Region 2016
    Figure 75: Merz Revenue (US$; Mn) & Y-o-Y Growth (%), 2013–2016

Copyright © Transparency Market Research, Inc. All Rights reserved